| Author | Study design | Number of patients (n) | Duration | Agent | Response | Bleeding events |
| Janczak [19] (2018) | Prospective, non-cirrhotic, Atypical sites | Total N=36 PVT N= 16 | ā | Rivaroxaban Apixaban
| Recurrence rate 7.3 % (n=2) (both had malignancy) | Minor N=1 (3.6%) Major N=2 (7.2%) |
| Qi [20] (2017) | Case report, cirrhotic, CPT not specified | SMV, splenic vein, N=1 | 11 weeks | Rivaroxaban | Recanalization | Melena and hematemesis |
| Nery [21] (2017) | Case report Non-cirrhotic | N=1 | >6m | Rivaroxaban 20 mg daily | Complete recanalization L branch, partial recanalization right branch | None |
| De Gottardi [10] (2016) | Retrospective, Both cirrhotic and non-cirrhotic, Splanchnic | Total, N= 94 PVT N= 80 (Non cirrh- N=38 Cirrh- N=22) | Non-cirrhotic 13.1 m cirrhotic 9.6 m | Rivaroxaban Apixaban Dabigatran
| Not studied | Cirrhosis: Minor, n=7, Major, n=2 Non-cirrh: Minor, n= 4 Major, n=1 |
| Hum [9] (2016) | Retrospective, Cirrhotic, CPT A, B & C All indications | Total, N= 27 PVT N=4 | ā | Rivaroxaban 15 mg bid +/- 20 mg daily load, Apixaban 5mg bid +/- 10mg bid load, No bridging | Recurrence rate 4% (n=1) | Major N=1 (4%) Minor, N=7 |
| Yang [12] (2016) | Case report, cirrhotic CPT A | N=1 | 6 m | Rivaroxaban 15 mg bid x 3 wks, then 20 mg/d | Complete recanalization | None |
| Intagliata [8] (2015) | Retrospective, cirrhotic, CPT A and B | Total N= 20 PVT, N=12 | 10.6 m | Apixaban Rivaroxaban | Not studied | Major, n=1
|
| Martinez [22] (2014) | Case report, Cirrhotics, CPT A | N=1 | 6 m | Rivaroxaban 20 mg /d | Complete recanalization | None |
| Lenz [11] (2014) | Case report, Cirrhotic CPT A | N=1 | 5 m | Rivaroxaban 10 mg daily | Complete recanalization | None |
| Pannach [23] (2013) | Case report, Non-cirrhotic | N=1 | >4 weeks | Rivaroxaban 20 mg daily | Complete recanalization | None |
|
|